Lord, Abbett & Co
RARX

Lord, Abbett & Co’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Lord, Abbett & Co’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-466,073
Closed -$11M – 750
2019
Q3 		$11M Buy
466,073
+41,211
+10% +$1.22M 0.04% 510
2019
Q2 		$12.8M Buy
424,862
+102,077
+32% +$2.34M 0.04% 508
2019
Q1 		$7.23M Buy
+322,785
New +$6.94M 0.02% 612

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co's RARX Position: Q4 2019 in Review

Lord, Abbett & Co sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 466,073 shares — an estimated $11M sold.

Lord, Abbett & Co first reported a position in RARX in Q1 2019 and held it in 3 quarters. The position peaked at $12.8M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

  • Lord, Abbett & Co reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Lord, Abbett & Co sold 466,073 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $11M.
  • Lord, Abbett & Co first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Lord, Abbett & Co's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12.8M in Q2 2019.
  • 146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Lord, Abbett & Co's 13F filing for Q4 2019, filed 14 Feb 2020.